Wataru Okamoto

7PUBLICATIONS
75CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Radiation therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.

Mitsuho Imai, Yoshiaki Nakamura, Sangwon Shin

|Aug 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

Naoko Iida, Mitsuho Imai, Wataru Okamoto

|Aug 05, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto

|Mar 30, 2023
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.

Yoshiaki Nakamura, Riu Yamashita, Wataru Okamoto

|Feb 11, 2023
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.

Shigeki Yano, Tomoki Kimura, Tomokazu Kawaoka

|Feb 21, 2022
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.

Yoshiaki Nakamura, Wataru Okamoto, Tadamichi Denda

Pageof 2

Frequent Collaborators

5 joint publications

Takayuki Yoshino

5 joint publications

Yoshiaki Nakamura

4 joint publications

Ken Kato

4 joint publications

Hideaki Bando